We need commercial UV disinfection technology that effectively reduces harmful pathogens, is safer for use in indoor spaces, and adds a layer of defense as part of a multi-disinfection strategy like regular cleaning.
Urbanization, worldwide population growth, and global travel contribute to diverse contact among people, livestock, and wildlife, increasing the frequency and transmission of new pathogens that may harm us. We need safe and effective disinfection technology that reduces pathogens now, and for the future.
Christie® CounterAct™ commercial UVC disinfection products with patented Care222® technology are designed to continually and effectively neutralize pathogens around people, like the coronavirus that causes COVID-19, in high-ceiling locations. Care222 is also the world’s first UVC technology with a proprietary optical filter that blocks potentially harmful longer UVC wavelengths from being emitted.
CounterAct products are now in production after receiving certification by both UL and CE, organizations that thoroughly test for stringent health, safety, environmental, and—most importantly—photobiological requirements for consumer safety.
CounterAct fixtures:
*Professional installation is recommended for Christie CounterAct products
We know ultraviolet (UV) light is highly effective in reducing pathogens—businesses have long used germicidal UVC light to disinfect spaces.
UVC light is a type of UV light that inactivates airborne and surface pathogens like viruses and bacteria by damaging their RNA and DNA.
Conventional germicidal lamps that emit UVC light with longer wavelengths (>230nm) effectively reduce pathogens but present a human health hazard to unprotected eyes and skin.
CounterAct products contain patented Care222 lamps that emit filtered far-UVC 222nm light, designed to continually and effectively inactivate pathogens with people present.
What’s new is the discovery and application of far-UVC 222nm light, a sweet spot on the UV spectrum that’s safer for humans because its limited range of penetration means it can’t penetrate past the protective outer layers of our skin and eyes.
The world’s first UVC technology with a proprietary optical filter that blocks potentially harmful UVC wavelengths from being emitted
Easy-to-service for straightforward lamp changes
Fixtures are available in black or white to fit existing color schemes
Instant on/off at full output power
Flexible leasing options are available
Available in AC power
As easy to install* as traditional commercial lighting fixtures, with maintenance via the CounterAct Configure app
Long-lasting – frequent on/off cycles don’t affect lifetime
Programmable – Configurable, automated operation within the limits of current ACGIH and IEC guidelines, which may be reconfigured if guidelines evolve over time
*Professional installation is recommended for Christie CounterAct products
Add a layer of defense to your indoor space with Christie CounterAct, designed to neutralize pathogens with people present while meeting established safety guidelines
A September 2020 study by researchers at Hiroshima University entitled Effectiveness of 222nm ultraviolet light on disinfecting SARS-CoV-2 surface contamination found that far-UVC 222nm light effectively reduced more than 99.7% of surface contamination of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19.
News media can download CounterAct information here or contact pr@christiedigital.com
As we experience unprecedented, global health challenges, we must use available technologies to combat the spread of pathogens.
Read more
Christie® set to mass produce CounterAct™ with Care222®, the safer, filtered far-UVC disinfection technology for use around people. Designed for occupied indoor venues, CounterAct is CE- and UL-compliant.
Read more
News of the mass production of CounterAct is featured in The McMorrow Reports Facility Management & Design.
Read more
Hotel Management magazine covers the announcement that CounterAct is in mass production.
Read more
Read Business Chief magazine’s coverage of the announcement that CounterAct is now in mass production.
See the full story
Given the ongoing battle with today’s pandemic, how can and should exhibitors make movie theatres COVID-safe? Read Screentrade magazine’s coverage UVC technology and CounterAct
Read more
A new study by Hiroshima University and Ushio showed that Care222 technology is equally effective in inactivating a SARS-CoV-2 variant as in activating the original strain.
Read more
Learn more about far-UVC light disinfection and how it can help attractions add an extra layer of defense against pathogens. Attend Blooloop’s first live discussion of their new Innovation Sessions series February 3 at 10:30 am ET / 3:30 pm GMT.
Register for this free online event
Coronavirus is airborne. So how do we clean the air that we breathe? Martin Howe, Blooloop, examines the potential of far-UVC technology to help theme parks and attractions reopen in a post-COVID world.
Read moreChristie introduces groundbreaking far-UVC light fixture with patented Care222 technology for UV disinfection that may be used around people.
Read more
Every year, Fortune highlights companies that have made measurable social or environmental impact. The article features Ushio’s achievements in developing Care222 filtered far-UVC disinfection modules.
Read more
The first-ever research study conducted on the efficacy of far-UVC 222nm light against SARS-CoV-2 shows that just 3 mJ/cm2 of 222nm light effectively inactivated more than 99.7% of viable samples.
Read more
We know COVID-19 is spread indoors through droplets transmitted through the air. A breakthrough Columbia University study identifies far-UVC light as an effective COVID killer.
Read more
Kobe University Graduate School of Medicine and Ushio sutdy prove 222nm far-UVC is effective for irradiation and safe for humans
Read more
Scientists at Columbia University prove that 222nm far-UVC light inactivates 99.9% of coronaviruses.
Read more
July, 2021
Hiroshima University
A new study by Hiroshima and Ushio showed that Care222 technology is equally effective in inactivating a SARS-CoV-2 variant as in activating the original strain.
January, 2021
University of St. Andrews
The results of this study suggest that filtering longer (>230nm) ultraviolet wavelengths in far-UVC devices is critical for human skin safety and advances the argument for ACGIH exposure limit expansion, which would subsequently enable faster inactivation of viruses.
December, 2020
Columbia University Irving Medical Center
This study compares filtered and unfiltered krypton-chloride (KrCl) excimer lamps and found a notable increase in allowable exposure when using a filter and supports the use of filters for far-UVC KrCl excimer lamps when used to limit disease transmission in occupied locations.
September, 2020
Hiroshima University
This study found that far-UVC 222nm light effectively reduced more than 99.7% of surface contamination of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19.
August, 2020
Kobe University
This study suggests that the filtered far-UVC light emitted by Care222 modules can be used to reduce pathogens while people are present. The study concludes that far-UVC (222nm) at 500 mJ/cm2 was a safe irradiation dose (despite being far stronger than current ACGIH threshold of 23 mJ/cm2 per 8-hour exposure) and possessed bactericidal effects, and that in the future, far-UVC (222nm) could be expected to contribute to the prevention of perioperative infection.
June, 2020
Columbia University Irving Medical Center
This study found that 99.9% of aerosolized seasonal coronaviruses (that cause the common cold) were inactivated when exposed to far-UVC 222nm light for 25 minutes.
May, 2020
Kobe University
This study investigated the long-term effects of far-UVC 222nm light on skin using highly photocarcinogenic phenotype mice. The results suggest that far-UVC 222nm lamps can be used as an alternative to 254nm, since 222nm exerts a comparable disinfection ability and can be safely used for disinfecting human skin.
February, 2017
Columbia University Irving Medical Center
This study suggests far-UVC 222nm light is as effective at killing (antibiotic-resistant) bacteria as conventional germicidal UV lamps that use 254nm light, but without associated skin damage risks.
Video length - (03:15)
Video length - (06:08)
Video length - (01:36)
Video length - (10:13)
Video length - (30:15)
Video length - (02:09)
Video length - (06:16)
All references to “disinfect”, “disinfecting” and “disinfection” refer generally to the reduction of pathogenic bioburden and are not intended to refer to any specific definition as may be used by any governmental or regulatory authority including the U.S. Food and Drug Administration and the U.S. Environmental Protection Agency. Christie CounterAct products with patented Care222 technology are not medical devices and are not to be used as or for medical devices. The pathogen-reducing efficacy of Christie CounterAct products and their use in occupied spaces is dependent on many site-specific factors as well as proper installation and operation within specifications and in accordance with American Conference of Governmental Institutional Hygienist (ACGIH) guidelines. Professional installation is recommended for Christie CounterAct products. The Care222® standard character mark and stylized logo mark are registered trademarks of Ushio America, Inc. in the United States, Japan, European Union, and United Kingdom.
